Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy

BMC Nephrology

Hong Zhang²  Suxia Wang¹  Xueying Li³  Sufang Shi²  Ying Liu²  Yuqing Chen²  Jingjing Zhou² 

[1] Laboratory of Electron Microscopy, Peking University First Hospital, Beijing 100034, China;Key Lab of Chronic Kidney Disease Prevention and Treatment, Ministry of Education, Beijing 100034, China;Department of Statistics, Peking University First Hospital, Beijing 100034, China

关键词: Tubulointerstitial lesions;    Plasma uric acid levels;    IgA nephropathy;   

Others  :  1082748
DOI  :  10.1186/1471-2369-15-11

 received in 2013-02-28, accepted in 2014-01-03,  发布年份 2014

【 摘 要 】

Background

Hyperuricemia appeared to be a common symptom in IgA nephropathy (IgAN), even in those with normal eGFR. IgAN was characterized by variation of pathological features, especially variable tubulointerstitial lesions. Since tubular reabsorption and excretion appeared to be more important in determination of plasma uric acid levels in persons without obvious decrease of glomerular filtration rate, we took advantage of our IgAN cohort to investigate whether plasma uric acid level associated with tubular interstitial lesions, and could be considered as a maker for tubular interstitial lesions, especially at early stage with normal eGFR.

Methods

623 IgAN patients were involved in the present study. Morphological changes were evaluated with Oxford classification scoring system as well as Beijing classification system of IgAN. Statistical analysis was done with SPSS 13.0.

Results

We found that plasma uric acid level associated with percentage of interstitial fibrosis/tubular atrophy. Higher plasma uric acid levels indicated higher tubulointerstitial scores, either with Oxford system (P = 0.012) or with Beijing classification system (P = 4.8*10^-4) in the whole cohort. We also found that in the subgroup of 258 IgAN cases with normal baseline eGFR (eGFR > =90 ml/min/1.73 M²), higher plasma uric acid associated with more severe tubulointerstitial lesions with Beijing scoring system (P = 3.4*10^-5). The risk of having more than 10% tubulointerstitial lesions in patients with hyperuricemia increased 58% compared with normal uric acid level. In subgroup with normal eGFR, only hyperuricemia predicted tubulointerstitial leisions, and the risk of having more tubulointerstitial changes increased 100%. Among these patients, hyperuricemia was associated with more tubulointerstitial lesions with a specificity of 60.3%. Specificity increased to 65% among those patients with eGFR > =90 ml/min/1.73 m².

Conclusions

Plasma uric acid levels indicate tubular interstitial lesions in IgAN and hyperuricemia may be considered as a marker for tubulointerstitial lesions.

【 授权许可】

   
2014 Zhou et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Syrjanen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000, 15:34-42.
• [2]Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004, 44:642-650.
• [3]Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50:239-247.
• [4]Chang HY, Tung CW, Lee PH, Lei CC, Hsu YC, Chang HH, Yang HF, Lu LC, Jong MC, Chen CY, Fang KY, Chao YS, Shih YH, Lin CL: Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 2010, 339:509-515.
• [5]Aringer M, Graessler J: Understanding deficient elimination of uric acid. Lancet 2008, 372:1929-1930.
• [6]Kutzing MK, Firestein BL: Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008, 324:1-7.
• [7]Mount DB, Kwon CY, Zandi-Nejad K: Renal urate transport. Rheum Dis Clin North Am 2006, 32:313-331.
• [8]Barratt J, Feehally J: IgA Nephropathy. J Am Soc Nephrol 2005, 16:2088-2097.
• [9]Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, Manns B, Hemmelgarn B: Histopathologic features aid in prediciton risk for progression of IgA nephropathy. Clin J Am Soc Nephrol 2010, 5:425-430.
• [10]Lv J, Zhang H, Zhou Y, Li G, Zou W, Wang H: Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton) 2008, 13:242-246.
• [11]Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007, 18:3177-3183.
• [12]D'Amico G: Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000, 36:227-237.
• [13]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
• [14]Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, et al.: The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009, 76:546-556.
• [15]Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, et al.: The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009, 76:534-545.
• [16]Jiang L, Liu G, Lv J, Huang C, Chen B, Wang S, Zou W, Zhang H, Wang H: Concise semiquantitative histological scoring system for immunoglobulin A nephropathy. Nephrology (Carlton) 2009, 14:597-605.
• [17]Myllymäki J, Honkanen T, Syrjänen J, Helin H, Rantala I, Pasternack A, Mustonen J: Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 2005, 20:89-95.
• [18]Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M: Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001, 87:333-339.
• [19]Berger L, Yu TF: Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 1975, 59:605-613.
• [20]Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, et al.: SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40:437-442.
• [21]Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002, 417:447-452.